Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

First Non-Chemotherapy Combination Regimen Receives FDA Approval for Leukemia and Lymphoma

First Non-Chemotherapy Combination Regimen Receives FDA Approval for Leukemia and Lymphoma

The United States Food and Drug Administration (FDA), for previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), approved obinutuzumab (Gazyva) combined with ibrutinib (Imbruvica) on 28 January 2019.

This is the first approval of a non-chemotherapy combination regimen for previously untreated CLL / SLL.

Ibrutinib monotherapy (single-agent treatment), an oral pill taken once daily, was already approved for first-line CLL / SLL.

After 2013, ibrutinib became an important CLL treatment. Alone—and now combined with obinutuzumab—it has become an important non-chemotherapy first-line option.

The new approval is based on iLLUMINATE phase-3 clinical trial results.

At a median follow-up of 31 months, ibrutinib plus obinutuzumab significantly improved progression-free survival compared with chlorambucil plus obinutuzumab. With Ibrutinib + obinituzumab, median progression-free survival had not yet been reached because over half remained responsive; in the other arm it was 19 months.

Compared with chlorambucil and obinutuzumab, ibrutinib and obinutuzumab produced a % 77 reduction in cancer progression or death risk.

High-risk patients treated with ibrutinib and obinutuzumab did better, with a % 85 reduction in progression or death risk. High risk in CLL and SLL is defined as 17p deletion / TP53 mutation, 11q deletion mutation, or unmutated IGHV. Overall response was % 89 with ibrutinib and obinutuzumab versus % 73 with chlorambucil plus obinutuzumab.

In patients treated with ibrutinib and obinutuzumab, the most common all-grade adverse effects (≥% 20) were neutropenia (% 48), thrombocytopenia (% 36), rash (% 36), diarrhea (% 34), musculoskeletal pain (% 33), bruising (% 32), cough (% 27), infusion-related reaction (% 25), bleeding (% 25), and arthralgia (% 22).

Warnings for this combination include bleeding, infection, cytopenia, cardiac arrhythmia, hypertension, second malignancy, tumor lysis syndrome, and embryo-fetal toxicity.

Related Topic:

Sources

FDA Approves First Nonchemo Regimen for CLL/SLL - Medscape - Jan 28, 2019.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

First Non-Chemotherapy Combination Regimen Receives FDA Approval for Leukemia and Lymphoma

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy